Article
Oncology
Paolo Nuciforo, John Townend, Martine J. Piccart, Shona Fielding, Panagiota Gkolfi, Sarra El-Abed, Evandro de Azambuja, Gustavo Werutsky, Judith Bliss, Volker Moebus, Marco Colleoni, Alvaro Moreno Aspitia, Henry Gomez, Andrea Gombos, Maria A. Coccia-Portugal, Ling-Ming Tseng, Georg Kunz, Guillermo Lerzo, Joohyuk Sohn, Vladimir Semiglazov, Cristina Saura, Judith Kroep, Antonella Ferro, David Cameron, Richard Gelber, Jens Huober, Serena Di Cosimo
Summary: Dual anti-HER2-targeted therapy combined with chemotherapy significantly improves the rate of pathological complete response (pCR) in breast cancer patients. However, limited data exist on the long-term impact of the increased pCR on survival.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, Chiara Maura Ciniselli, Sara Pizzamiglio, Lorenzo Castagnoli, Matteo Dugo, Barbara Galbardi, Roberto Salgado, Sherene Loi, Stefan Michiels, Tiziana Triulzi, Elda Tagliabue, Sarra El-Abed, Miguel Izquierdo, Evandro de Azambuja, Paolo Nuciforo, Jens Huober, Luca Moscetti, Wolfgang Janni, Maria Antonia Coccia-Portugal, Paola Antonia Corsetto, Antonino Belfiore, Daniele Lorenzini, Maria Grazia Daidone, Andrea Vingiani, Luca Gianni, Serenella Maria Pupa, Giampaolo Bianchini, Giancarlo Pruneri, Claudio Vernieri
Summary: This study found that high expression of CD36 is associated with worse clinical outcomes in early-stage HER2+ BC patients treated with anti-HER2 therapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Multidisciplinary Sciences
Stephanie Cabarcas-Petroski, Gabriella Olshefsky, Laura Schramm
Summary: This study analyzed breast cancer datasets and found amplification of MAF1 in breast cancer, which is associated with other genes. MAF1 expression is significantly increased in HER2-positive breast cancer and is related to the prognosis of trastuzumab treatment.
Article
Oncology
Xuexin He, Jiali Ji, Xiaolan Dai, Aiham Z. Qdaisat, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching J. Yeung
Summary: This study reviewed early HER2-positive breast cancer patients at the institution from 1998 to 2009 and found that hypertension and history of coronary artery disease were independent prognostic factors for late severe CV events. Combining anthracycline and anti-HER2 therapy regimens was beneficial for improving overall survival.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Michelle D. Hackshaw, Heather E. Danysh, Mackenzie Henderson, Eric Wang, Nora Tu, Zahidul Islam, Amy Ladner, Mary E. Ritchey, Maribel Salas
Summary: Patients with HER2+ breast cancer who develop brain metastasis typically have poor prognosis. Factors such as younger age, hormone receptor status, tumor size and treatment regimens can affect time to brain metastasis diagnosis and survival after diagnosis. Combination therapies including trastuzumab and lapatinib or trastuzumab and pertuzumab show promise in improving survival in these patients. More research is needed to understand risk factors for brain metastasis and improve treatment options.
Article
Oncology
Francesco Schettini, Aleix Prat
Summary: HER2-positive breast cancer is a complex and multifaceted disease with interesting therapeutic implications, including differentiating between molecular subtypes, a wide range of DNA alterations, and the predictive role of lymphocyte infiltration. Future research may focus on developing more personalized treatment approaches based on molecular characteristics.
Article
Oncology
I-Chun Chen, Fu-Chang Hu, Ching-Hung Lin, Shu-Min Huang, Dwan-Ying Chang, Ann-Lii Cheng, Yen-Shen Lu
Summary: The meta-analysis results revealed that in patients with HER2-positive metastatic breast cancer, treatment with anti-HER2 antibodies led to a prolongation of OS more than PFS, with the absolute increment in median OS time being double that of median PFS time, and this increase was linearly correlated, indicating the need for further investigation into the efficacy of anti-HER2 antibodies.
Article
Oncology
Martina Di Modica, Giorgio Gargari, Viola Regondi, Arianna Bonizzi, Stefania Arioli, Beatrice Belmonte, Loris De Cecco, Elena Fasano, Francesca Bianchi, Alessia Bertolotti, Claudio Tripodo, Laura Villani, Fabio Corsi, Simone Guglielmetti, Andrea Balsari, Tiziana Triulzi, Elda Tagliabue
Summary: The study reveals that gut microbiota play a direct role in the efficacy of trastuzumab, suggesting that manipulation of gut microbiota could be an effective strategy for treatment. The findings demonstrate that antibiotics can impact the recruitment and activation of immune cells in tumors, leading to reduced effectiveness of trastuzumab.
Article
Multidisciplinary Sciences
Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip, Adnan Aydiner
Summary: The purpose of this study was to evaluate the prognosis and predictors of complete response for HER2-positive metastatic breast cancer patients receiving long-term trastuzumab-based therapy. Binary regression analysis was used to analyze the predictors of complete response. A total of 80 patients were included in the study, with a median trastuzumab treatment duration of 62 months. A complete response was observed in 75% of patients, with a median duration of 14.8 months. Menopausal status, the number of metastatic sites, and the use of endocrine therapy with trastuzumab were found to be significant predictors of complete response. The study highlights the potential of trastuzumab-based therapy for achieving complete cure in HER2-positive metastatic breast cancer patients, but further multicenter studies are needed to confirm these findings.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Byeongju Kang, Jeeyeon Lee, Jin Hyang Jung, Wan Wook Kim, Heejung Keum, Ho Yong Park
Summary: The clinical features and prognosis of breast cancer vary depending on the molecular subtype, especially in the case of luminal B breast cancer. This study examined the clinicopathologic factors and survival rates of luminal B breast cancer based on HER2 status. The results showed that survival differed significantly based on molecular subtype, and treatment with neoadjuvant chemotherapy also impacted prognosis.
Article
Multidisciplinary Sciences
Alma Andersson, Ludvig Larsson, Linnea Stenbeck, Fredrik Salmen, Anna Ehinger, Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Roden, Alex Swarbrick, Ake Borg, Jonas Frisen, Camilla Engblom, Joakim Lundeberg
Summary: This study utilized Spatial Transcriptomics technology to investigate gene expression in HER2-positive breast tumors, identifying shared gene signatures for immune and tumor processes and developing a predictive model for cellular interactions.
NATURE COMMUNICATIONS
(2021)
Article
Chemistry, Medicinal
Fangfang Duan, Chenge Song, Yuyu Ma, Kuikui Jiang, Fei Xu, Xiwen Bi, Jiajia Huang, Ruoxi Hong, Zhangzan Huang, Qianyi Lu, Zhongyu Yuan, Shusen Wang, Wen Xia
Summary: This study aimed to develop prognostic nomogram models for patients with HR+, HER2- metastatic breast cancer treated with everolimus. Three independent prognostic factors were identified, and predictive models for PFS and OS were established with favorable discrimination and calibration. The nomogram models showed good performance in terms of accuracy, discrimination capacity, and clinical application value.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Review
Oncology
Santiago Duro-Sanchez, Macarena Roman Alonso, Joaquin Arribas
Summary: A variety of treatments are available for HER2-positive breast cancer, but resistance to these therapies is common and associated with poor prognosis. Immunotherapeutic approaches are being explored to eradicate tumor cells and prevent relapse and progression. This review discusses the different immunotherapeutic strategies being tested and their potential benefits for HER2-positive breast cancer.
Article
Multidisciplinary Sciences
Yutian Zou, Shaoquan Zheng, Xinhua Xie, Feng Ye, Xiaoqian Hu, Zhi Tian, Shu-Mei Yan, Lu Yang, Yanan Kong, Yuhui Tang, Wenwen Tian, Jindong Xie, Xinpei Deng, Yan Zeng, Zhe-Sheng Chen, Hailin Tang, Xiaoming Xie
Summary: FGFR4 inhibition enhances sensitivity to anti-HER2 treatment in resistant breast cancer cells by triggering ferroptosis.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Ana C. C. Garrido-Castro, Meredith M. M. Regan, Samuel M. M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. M. Rosenbluth, Caroline Block, Laura E. E. Warren, Jennifer R. R. Bellon, Eren Yeh, Beth T. T. Harrison, Elizabeth Troll, Nancy U. U. Lin, Sara M. M. Tolaney, Beth Overmoyer, Filipa Lynce
Summary: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, presenting as de novo metastatic disease in a significant portion of cases. Limited research has been conducted on the utilization of locoregional therapy after HER2-directed systemic therapy in these patients, as well as their locoregional progression and survival outcomes. A study identified patients with de novo HER2-positive metastatic IBC and evaluated their treatment data and outcomes. The findings suggest that surgery after systemic therapy may lead to favorable outcomes, with good locoregional control and prolonged survival observed.